Article 6-1-1702. Developer responsibilities - documentation.

5 obligations

CO-ADMT-6-1-1702-01 Transparency

Provide General Statement of Intended and Harmful Uses

A developer must make available to each deployer of a covered ADMT a general statement describing the intended uses and

CO-ADMT-6-1-1702-02 Transparency

Disclose Training Data Categories

A developer must provide deployers with a description of the categories of data, including personal data, used to train

CO-ADMT-6-1-1702-03 Transparency

Disclose Known Limitations and Risks

A developer must disclose to deployers the known limitations of the covered ADMT, including known risks and circumstance

CO-ADMT-6-1-1702-05 Transparency

Provide Information Necessary for Deployer Compliance

A developer must provide deployers with information reasonably necessary for the deployer to comply with Section 6-1-170

CO-ADMT-6-1-1702-06 Transparency

Notify Deployer of Withheld Information

If a developer withholds information otherwise required under subsection (1), the developer must notify the deployer tha

Article 6-1-1704. Deployer disclosures - point-of-interaction notice -

6 obligations

CO-ADMT-6-1-1704-01 Transparency

Pre-Use Notice of Covered ADMT to Consumer

Prior to using a covered ADMT to materially influence a consequential decision, the deployer must provide a clear and co

CO-ADMT-6-1-1704-02 Transparency

Public Posting as Compliance Method for Pre-Use Notice

A deployer may satisfy the pre-use notice requirement in subsection (1) by maintaining a prominent public notice that is

CO-ADMT-6-1-1704-03 Transparency

Post-Adverse Outcome Disclosure: Description of Decision and ADMT Role

If a deployer uses a covered ADMT to materially influence a consequential decision resulting in an adverse outcome for a

CO-ADMT-6-1-1704-04 Transparency

Post-Adverse Outcome Disclosure: Instructions to Request Additional Information

Within thirty days of an adverse outcome decision involving a covered ADMT, the deployer must provide instructions and a

CO-ADMT-6-1-1704-05 Transparency

Post-Adverse Outcome Disclosure: Explanation of Consumer Rights

Within thirty days of an adverse outcome decision involving a covered ADMT, the deployer must provide an explanation of

CO-ADMT-6-1-1704-06 Transparency

Notify Consumer When Withholding Trade Secret Information

If a deployer withholds information from disclosure under this section because it constitutes a trade secret or is other

Article 6-1-1708. Compliance with other legal obligations - insurers -

6 obligations

CO-ADMT-6-1-1708-01 Transparency

Insurer Disclosure When Not Deemed Compliant

If an insurer (as defined in section 10-1-102(13)) and affiliated entities subject to section 10-3-1104.9 are not deemed

CO-ADMT-6-1-1708-02 Transparency

General Notice of Advanced Technology Use to Patients

A covered entity (as defined under HIPAA, 42 U.S.C. Secs. 1320d to 1320d-9, and its implementing regulations, or a busin

CO-ADMT-6-1-1708-03 Transparency

Financial Assistance Eligibility - Plain Language Decision Description

A covered entity that uses a covered ADMT to determine a patient's eligibility for financial assistance, including disco

CO-ADMT-6-1-1708-04 Transparency

Financial Assistance Eligibility - Disclosure of Information Relied Upon

A covered entity using a covered ADMT to determine financial assistance eligibility must disclose to the patient the typ

CO-ADMT-6-1-1708-05 Transparency

Financial Assistance Eligibility - Correction Request Information

A covered entity using a covered ADMT to determine financial assistance eligibility must inform the patient how to reque

CO-ADMT-6-1-1708-07 Transparency

Timing of Financial Assistance Disclosures

A covered entity may satisfy the financial assistance eligibility disclosure requirements (subsection (3)(d)) either thr